Stockreport

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 [Yahoo! Finance]

Immix Biopharma, Inc.  (IMMX) 
PDF First cohort at 150 million CAR+T cells already successfully completed Each of these two doses have produced complete responses in prior clinical studies Lead site M [Read more]